Microvisk (Denbighshire, Wales) won European CE Mark approval for the CoagMax PT/INR blood clotting analyzer that uses a novel micro electro mechanical (MEMS) component at the core of its sensor. The CoagMax uses disposable strips that have a tiny cantilever built in. Show More Summary
In an analysis of the results of nearly 50 randomized trials that examined treatments of venous thromboembolisms (blood clot in a vein), when compared with the low-molecular-weight heparin-vitamin K antagonist combination, there were...Show More Summary
American Idol finalist Michael Johns’ death in August wasn’t caused by a blood clot but was a result of his abuse of alcohol, according to his best friend, who claims Michael Johns’ wife covered up the real reason. However, she says he’s been harassing her. The two engaged in a legal dispute in which Torrey Gambill quotes texts... read more »
Two independent groups of researchers led by Sidney (Wally) Whiteheart, PhD, of the University of Kentucky, and Charles Lowenstein, MD, of the University of Rochester, have published important studies exploring the role that a gene called STXBP5 plays in the development of cardiovascular disease.
Ottawa – September 16, 2014 – Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer. Show More Summary
In an analysis of the results of nearly 50 randomized trials that examined treatments of venous thromboembolisms (blood clot in a vein), there were no significant differences in clinical and safety outcomes associated with most treatment...Show More Summary
By Don Dion: rEVO Biologics, Inc. (Pending:RBIO), a biopharmaceutical firm seeking to develop and commercialize specialty therapeutics for patients with blood clotting disorders, plans to raise $50.4 million in its upcoming IPO. The Framingham, Massachusetts-based firm will offer 3.6 million shares at an expected price range of $13-$15 per share. Show More Summary
Blood clots – a major challenge in the quest to build replacement kidneys in the lab – have been addressed by regenerative medicine researchers at Wake Forest Baptist Medical Center, citing work reported in journal Technology. The scientists, working with human-sized pig kidneys, developed the most successful method to date to keep blood vessels in […]
A new class of synthetic platelet-like particles could augment natural blood clotting for the emergency treatment of traumatic injuries - and potentially offer doctors a new option for curbing surgical bleeding and addressing certain blood clotting disorders without the need for transfusions of natural platelets.
When someone is bleeding, a blood clot is a positive response -- the body forms the clot as a plug to stop bleeding. But when blood clots form in the absence of an injury, those clots can be life-threatening. Excessive blood clots in arteries and the brain are the main cause of heart attack and stroke. Show More Summary
Kayla Katler, 21, was six months pregnant when doctors discovered she had a blood clot and she suffered a deadly seizure. Her son Brayden was born by emergency C-section and survived and now the little tot is headed home from the hospital. After six weeks, he is healthy enough to go home with dad, Derek […]
TORONTO, Sept. 2, 2014 – In injured mice, the naturally occurring protein fibronectin is instrumental in stopping bleeding but interestingly also at preventing life-threatening blood clots – according to new research published today in Journal of Clinical Investigation. read more
Aspirin may be a promising alternative for those who can't take long-term anticoagulant drugs that prevent clots from reoccurring in the veins, according to new research in the American Heart Association journal Circulation. read mo...
Low dose aspirin lowers the occurrence of new venous blood clots – and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published...Show More Summary
Necessary for blood clotting, vitamin K does not transfer through the placenta during birth. This leaves babies with very little of the nutrient in their systems when they are born, putting them at risk for haemorrhagic disease of the newborn (HDN) at birth. Show More Summary
The Philadelphia Flyers announced they signed defenseman Michael Del Zotto to a one-year, $1.3 million contract last week to replace Kimmo Timonen, who is out indefinitely with blood clots in his lungs and body. Del Zotto is only 24 years old. Show More Summary
Doctors, nurses, midwives and doulas will debate healthy labor and delivery practices - including the use of the synthetic hormone Pitocin to hasten childbirth and vitamin K to speed blood clotting in newborns -- at the third annual Cedars-Sinai Birth Community Day, Aug. 14.
Many more stroke patients could benefit from thrombolytic treatment (the use of drugs to break up or dissolve blood clots), but it needs to be administered as quickly as possible after the first signs of illness, according to new findings from the largest meta-analysis to date investigating the clot-busting drug alteplase. The study involved more than 6700 stroke patients.
The Philadelphia Flyers are slowly becoming a better team. Now, they will need some luck. After signing defenseman Kimmo Timonen, a 15-year veteran, to a one-year contract valued at $2 million, doctors in Timonen’s home country of Finland have diagnosed Timonen with blood clots, according to NHL.com. Flyers new general manager Ron Hextall announced in
Many more stroke patients could benefit from thrombolytic treatment (the use of drugs to break up or dissolve blood clots), but it needs to be administered as quickly as possible after the first signs of illness, according to new findings from the largest meta-analysis to date investigating the clot-busting drug alteplase. Show More Summary